CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.17B, above the global median of $1.15B
- PositionDebt-to-equity is 5.55×, higher than 95% of its Medical Devices peers (median 0.21×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.17BUSDvs all stocks (USD)
Revenue (TTM)
1.03BUSDvs all stocks (USD)
Profit Margin
-9.20%vs Medical Devices peers
Beta
1.58xvs all stocks
52-Week Change
16.75%vs all stocks
Market Capitalization
1.17BUSDvs all stocks (USD)
Enterprise Value
1.33BUSDvs all stocks (USD)
Forward P/E
150.13xvs Medical Devices peers
Price to Sales (TTM)
1.14xvs Medical Devices peers
Price to Book (MRQ)
8.84xvs Medical Devices peers
Enterprise to Revenue
1.30xvs Medical Devices peers
Enterprise to EBITDA
-30.90xvs Medical Devices peers
Gross Margin
55.33%vs Medical Devices peers
Profit Margin
-9.20%vs Medical Devices peers
Operating Margin
-7.05%vs Medical Devices peers
Return on Assets (TTM)
-3.68%vs Medical Devices peers
Return on Equity (TTM)
-65.73%vs Medical Devices peers
Revenue (TTM)
1.03BUSDvs all stocks (USD)
Revenue per Share (TTM)
15.16USDUpdated Jul 19, 2026Quarterly Revenue Growth
5.50%vs Medical Devices peers
Gross Profit (TTM)
564.40MUSDvs all stocks (USD)
EBITDA (TTM)
-43.20MUSDvs all stocks (USD)
Net Income (TTM)
-94.55MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
19.61MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-20.26MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.01BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
468.72MUSDFY2025 · Dec 31, 2025Gross Profit
546.01MUSDFY2025 · Dec 31, 2025Operating Income
-167.31MUSDvs all stocks (USD)
Pre-tax Income
-200.27MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.44MUSDFY2025 · Dec 31, 2025Net Income
-204.71MUSDFY2025 · Dec 31, 2025EBIT
-194.22MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-156.61MUSDFY2025 · Dec 31, 2025Research & Development
268.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
444.99MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.05MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.04USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.04USDFY2025 · Dec 31, 2025Basic Shares Outstanding
67.28MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
67.28MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.71MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-19.81MUSDFY2025 · Dec 31, 2025Free Cash Flow
-39.76MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
90.63MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.06MUSDFY2025 · Dec 31, 2025Interest Paid
5.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.71MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
17.67MUSDFY2025 · Dec 31, 2025Stock-based Compensation
92.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
88.14MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-56.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.23MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
41.30MUSDFY2025 · Dec 31, 2025Capital Expenditures
-19.95MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-78.59MUSDFY2025 · Dec 31, 2025Purchase of Investments
-85.66MUSDFY2025 · Dec 31, 2025Sale of Investments
257.07MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
151.46MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-40.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.76MUSDFY2025 · Dec 31, 2025Shares Outstanding
68.50MSharesUpdated Jul 19, 2026Float Shares
62.92MSharesUpdated Jul 19, 2026Shares Short
12.73MSharesUpdated Jul 19, 2026Short Ratio
5.05daysvs all stocks
Short % of Shares Outstanding
25.01%vs all stocks
% Held by Insiders
0.97%vs all stocks
% Held by Institutions
117.83%vs all stocks
Total Cash (MRQ)
570.26MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.32USDUpdated Jul 19, 2026Total Debt (MRQ)
734.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.55xvs Medical Devices peers
Current Ratio (MRQ)
3.58xvs Medical Devices peers
Book Value per Share (MRQ)
1.93USDUpdated Jul 19, 2026Total Assets
881.11MUSDvs all stocks (USD)
Total Current Assets
618.14MUSDFY2025 · Dec 31, 2025Total Liabilities
725.94MUSDFY2025 · Dec 31, 2025Total Non-current Assets
262.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
483.22MUSDFY2025 · Dec 31, 2025Total Current Liabilities
242.72MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
90.63MUSDFY2025 · Dec 31, 2025Other Short-term Investments
202.03MUSDFY2025 · Dec 31, 2025Accounts Receivable
165.49MUSDFY2025 · Dec 31, 2025Inventory
128.77MUSDFY2025 · Dec 31, 2025Accounts Payable
47.07MUSDFY2025 · Dec 31, 2025Short-term Debt
19.47MUSDFY2025 · Dec 31, 2025Deferred Revenue
9.53MUSDFY2025 · Dec 31, 2025Other Current Liabilities
75.24MUSDFY2025 · Dec 31, 2025Long-term Debt
425.00MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
49.74MUSDFY2025 · Dec 31, 2025Common Stock (Book)
68.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.25BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
155.17MUSDvs all stocks (USD)
52-Week Low
9.98USDUpdated Jul 19, 202652-Week High
29.65USDUpdated Jul 19, 202652-Week Change
16.75%vs all stocks
Beta
1.58xvs all stocks
50-Day MA
15.95USDUpdated Jul 19, 2026200-Day MA
18.82USDUpdated Jul 19, 2026Avg 10-Day Volume
1.64MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.09MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.37USDUpdated Jul 19, 2026Other Income / Expense
-34.15MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 5.55×, higher than 95% of its Medical Devices peers (median 0.21×)Significant
Debt-to-equity: 5.55Industry median: 0.21Industry P95: 3.06Peers compared: 59.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: -0.09
Significant cash reserves alongside high leverageNotable
Cash (USD): 570,256,000Total Debt (USD): 734,734,976Debt-to-Equity: 5.55
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.58Altman Z-Score: -0.09
Financial Health
Altman Z-Score -0.09: distress zoneCritical
Altman Z-Score: -0.09
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.17B, above the global median of $1.15BNotable
Market cap (USD): 1,170,476,840Global Median: 1,146,734,693.424
Revenue is $1.03B, above the global median of $520.53MNotable
Revenue (USD): 1,027,534,976Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioGaia AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangzhou Wondfo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Newell Brands Inc.
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone
Rapid7 Inc.
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone
Forward Air Corporation
3 interpretationsElevated Leverage on Three DenominatorsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedWithin or Near the Altman Distress Zone